Literature DB >> 10390601

Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.

H N Jayaram1, D A Cooney, M Grusch, G Krupitza.   

Abstract

Inosine 5 -monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme for the synthesis of GTP and dGTP. Two isoforms of IMPDH have been identified. IMPDH Type I is ubiquitous and predominantly present in normal cells, whereas IMPDH Type II is predominant in malignant cells. IMPDH plays an important role in the expression of cellular genes, such as p53, c-myc and Ki-ras. IMPDH activity is transformation and progression linked in cancer cells. IMPDH inhibitors, tiazofurin, selenazofurin, and benzamide riboside share similar mechanism of action and are metabolized to their respective NAD analogues to exert antitumor activity. Tiazofurin exhibits clinical responses in patients with acute myeloid leukemia and chronic myeloid leukemia in blast crisis. These responses relate to the level of the NAD analogue formed in the leukemic cells. Resistance to tiazofurin and related IMPDH inhibitors relate mainly to a decrease in NMN adenylyltransferase activity. IMPDH inhbitors induce apoptosis. IMPDH inhitors are valuable probes for examining biochemical functions of GTP as they selectively reduce guanylate concentration. Incomplete depletion of cellular GTP level seems to down-regulate G-protein function, thereby inhibit cell growth or induce apoptosis. Inosine 5'-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) catalyzes the dehydrogenation of IMP to XMP utilizing NAD as the proton acceptor. Studies have demonstrated that IMPDH is a rate-limiting step in the de novo synthesis of guanylates, including GTP and dGTP. The importance of IMPDH is central because dGTP is required for the DNA synthesis and GTP plays a major role not only for the cellular activity but also for cellular regulation. Two isoforms of IMPDH have been demonstrated. IMPDH Type I is ubiquitous and predominately present in normal cells, whereas the IMPDH Type II enzyme is predominant in malignant cells. Although guanylates could be salvaged from guanine by the enzyme hypoxanthine-guanine phosphoribosyltransferase (EC 2.4.2.8), the level of circulating guanine is low in dividing cells and this route is probably insufficient to satisfy the needs of guanylates in the cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390601

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  18 in total

1.  Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.

Authors:  A Bianchi-Smiraglia; J A Wawrzyniak; A Bagati; E K Marvin; J Ackroyd; S Moparthy; W Bshara; E E Fink; C E Foley; G E Morozevich; A E Berman; D S Shewach; M A Nikiforov
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

2.  Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Ying He; Zhousan Zheng; Yi Xu; Huiwen Weng; Ying Gao; Kai Qin; Jian Rong; Cui Chen; Miao Yun; Jiaxing Zhang; Sheng Ye
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 3.  The targets of curcumin.

Authors:  Hongyu Zhou; Christopher S Beevers; Shile Huang
Journal:  Curr Drug Targets       Date:  2011-03-01       Impact factor: 3.465

4.  Apoptotic signaling induced by benzamide riboside: an in vitro study.

Authors:  Sujata Pathak; Chandresh Sharma; H N Jayaram; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2009-03-05       Impact factor: 3.396

5.  A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion.

Authors:  Joseph A Wawrzyniak; Anna Bianchi-Smiraglia; Wiam Bshara; Sudha Mannava; Jeff Ackroyd; Archis Bagati; Angela R Omilian; Michael Im; Natalia Fedtsova; Jeffrey C Miecznikowski; Kalyana C Moparthy; Shoshanna N Zucker; Qianqian Zhu; Nadezhda I Kozlova; Albert E Berman; Keith S Hoek; Andrei V Gudkov; Donna S Shewach; Carl D Morrison; Mikhail A Nikiforov
Journal:  Cell Rep       Date:  2013-10-17       Impact factor: 9.423

6.  Novel synthetic route to the C-nucleoside, 2-deoxy benzamide riboside.

Authors:  Rebecca R Midtkandal; Philip Redpath; Samuel A J Trammell; Simon J F Macdonald; Charles Brenner; Marie E Migaud
Journal:  Bioorg Med Chem Lett       Date:  2012-06-28       Impact factor: 2.823

7.  Characterization of oxidized guanosine 5'-triphosphate as a viable inhibitor of soluble guanylyl cyclase.

Authors:  Celeste Bolin; Fernando Cardozo-Pelaez
Journal:  Free Radic Biol Med       Date:  2009-01-10       Impact factor: 7.376

8.  Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.

Authors:  Jörg Fellenberg; Pierre Kunz; Heiner Sähr; Daniela Depeweg
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

9.  Integrative analysis of circadian transcriptome and metabolic network reveals the role of de novo purine synthesis in circadian control of cell cycle.

Authors:  Ying Li; Guang Li; Benjamin Görling; Burkhard Luy; Jiulin Du; Jun Yan
Journal:  PLoS Comput Biol       Date:  2015-02-25       Impact factor: 4.475

10.  Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases.

Authors:  Rubén M Buey; Rodrigo Ledesma-Amaro; Adrián Velázquez-Campoy; Mónica Balsera; Mónica Chagoyen; José M de Pereda; José L Revuelta
Journal:  Nat Commun       Date:  2015-11-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.